Ref (type)	Population	Outcome, Interventions	Results and statistical analysis	Effect size	Favours
Adverse effects
RCT 6-armed trial	709 women with vulvovaginal candidiasis; analysis of 580 women, not by intention to treat (women with other vaginal infections excluded). In review	Adverse effects with butoconazole 2% for 3 days (intravaginal cream) with butoconazole 2% for 6 days (intravaginal cream) with miconazole 2% for 3 days (intravaginal cream) with placebo
RCT 3-armed trial	95 women with clinically and mycologically confirmed vulvovaginal candidiasis; analysis of 90 women, not by intention to treat (see Further information on studies) In review	Adverse effects 1/23 (4%) with clotrimazole for 3 days (intravaginal tablets) 9/22 (41%) with placebo (oral)	Significance not assessed
RCT	37 women with clinically and mycologically confirmed vulvovaginal candidiasis (women in first trimester of pregnancy, women with diabetes or with other vaginal infections, and women using contraceptive foams or jellies were excluded)	Adverse effects with clotrimazole for 1 day (intravaginal tablet) with placebo